Berberine Derivative B68 Promotes Tumor Immune Clearance by Dual‐Targeting BMI1 for Senescence Induction and CSN5 for PD‐L1 Degradation
Advanced Science · 2025-02 · 12 (7)
DOI: 10.1002/advs.202413122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 25.12.2024. Verfasst von Hongmei Hu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Tradi…. Hauptthemen laut MEDLINE: Berberine, Cellular Senescence, B7-H1 Antigen, Polycomb Repressive Complex 1. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Shanghai Municipal Science and Technology Major Project.
Abstract (Originalsprache)
Promoting tumor cell senescence arrests the cell cycle of tumor cells and activates the immune system to eliminate these senescent cells, thereby suppressing tumor growth. Nevertheless, PD‐L1 positive senescent tumor cells resist immune clearance and possess the ability to secret various cytokines and inflammatory factors that stimulate the growth of tumor cells. Consequently, drugs capable of both triggering senescence in tumor cells and concurrently diminishing the expression of PD‐L1 to counteract immune evasion are urgently needed. Here, a berberine derivative B68 is developed, which specifically induces tumor cell senescence by targeting BMI1. B68 also involves the degradation of PD‐L1 by targeting CSN5, thereby disrupting the immunosuppressive PD‐1/PD‐L1 interaction and enabling rapid clearance of senescent tumor cells. This approach simultaneously inhibits tumor progression and activates T cell immunity, as evidenced by the robust antitumor response following B68‐induced immunization of senescent cancer cells. Moreover, the synergistic effect of B68 with anti‐CTLA4 therapy further enhances antitumor immunity, and its ability to induce senescence in cancer cells triggers a strong protective response by dendritic and CD8 + T cells. These findings provide a scientific basis for developing a new tumor treatment strategy based on senescence induction and lay the foundation for further preclinical research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
- State Key Laboratory of Chemical Biology, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
- University of Chinese Academy of Sciences, Beijing, 100049, China.
- Department of Phytochemistry, School of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
- State Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
- Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
ORCID-Profile: Sanhong Liu
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Shanghai Municipal Science and Technology Major Project
- Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine
- Science and Technology Commission of Shanghai Municipality
- Organizational Key Research and Development Program of Shanghai University of Traditional Chinese Medicine
Zitieren
APA
Hu, H., Wang, Q., Yu, D., Tao, X., Guo, M., Tian, S., Zhang, Q., Xu, M., Geng, X., Zhang, H., Xu, H., Li, L., Xie, S., Chen, K., Zhu, W., Li, X. W., Xu, H., Li, B., Zhang, W., & Liu, S. (2025). Berberine Derivative B68 Promotes Tumor Immune Clearance by Dual‐Targeting BMI1 for Senescence Induction and CSN5 for PD‐L1 Degradation. Advanced Science, 12(7). https://doi.org/10.1002/advs.202413122
Vancouver
Hu H, Wang Q, Yu D, Tao X, Guo M, Tian S, et al. Berberine Derivative B68 Promotes Tumor Immune Clearance by Dual‐Targeting BMI1 for Senescence Induction and CSN5 for PD‐L1 Degradation. Advanced Science. 2025;12(7). doi:10.1002/advs.202413122
BibTeX
@article{Hu2025,
author = {Hu, Hongmei and Wang, Qun and Yu, Dianping and Tao, Xiaoyu and Guo, Mengmeng and Tian, Saisai and Zhang, Qing and Xu, Mengting and Geng, Xiangxin and Zhang, Hongwei and Xu, Hanchi and Li, Linyang and Xie, Shize and Chen, Kaixian and Zhu, Weiliang and Li, Xu-Wen and Xu, Hanchen and Li, Bo and Zhang, Weidong and Liu, Sanhong},
title = {Berberine Derivative B68 Promotes Tumor Immune Clearance by Dual‐Targeting BMI1 for Senescence Induction and CSN5 for PD‐L1 Degradation},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {7},
doi = {10.1002/advs.202413122}
}
EUVIMED